| |
| Issue |
Title |
| |
| Vol 64, No 8 (2024) |
Laboratory Aspects of Using the Results of NT-Probnp Concentration Immunochemical Determination in the Management of Patients With Heart Failure: Support For Clinical Decision-Making |
Abstract
PDF (Rus)
PDF (Eng)
|
|
N. G. Vinogradova, V. S. Berestovskaya, Z. N. Blankova, T. V. Vavilova, N. V. Gomyranova, V. P. Masenko, V. Yu. Mareev, A. A. Skvortsov, N. A. Sorokina, S. N. Tereshchenko |
| |
| Vol 63, No 4 (2023) |
Prospects for use of Vericiguat in HFrEF: Implications of VICTORIA Trial Results. Advisory Board Summary |
Abstract
PDF (Rus)
|
|
Yu. N. Belenkov, G. P. Arutyunov, V. Yu. Mareev, N. A. Koziolova, M. Yu. Sitnikova, F. T. Ageev, S. R. Gilyarevsky, A. I. Chesnikova, S. S. Yakushin, N. B. Perepech, Yu. V. Mareev |
| |
| Vol 60, No 1 (2020) |
Position Paper. The role of iron deficiency in patients with chronic heart failure and current corrective approaches |
Abstract
PDF (Rus)
PDF (Eng)
|
|
V. Yu. Mareev, S. R. Gilyarevskiy, Yu. V. Mareev, Yu. L. Begrambekova, Yu. N. Belenkov, Yu. A. Vasyuk, A. S. Galyavich, G. E. Gendlin, M. G. Glezer, Zh. D. Kobalava, T. A. Lelyavina, Ya. A. Orlova, I. V. Fomin, I. I. Shaposhnik |
| |
| Vol 59, No 5S (2019) |
Improvement of outcomes in patients with recent acute coronary syndrome: the place of PCSK9 inhibitors. The Resolution of National Advisory Board |
Abstract
PDF (Rus)
|
|
N. M. Akhmedzhanov, N. N. Vezikova, M. I. Voevoda, A. S. Galyavich, V. S. Gurevich, D. V. Duplyakov, M. V. Ezhov, Yu. A. Karpov, V. V. Kashtalap, G. A. Konovalov, O. G. Smolenskaya, A. N. Yakovlev |
| |
| Vol 59, No 5S (2019) |
Possibilities of clinical use of ezetimibe Otrio (JSC “AKRIKHIN”, Russia) in patients with high and very high cardiovascular risk who have not reached the target values of lipid metabolism. Conclusion of the Board of experts |
Abstract
PDF (Rus)
|
|
J. D. Kobalava, V. S. Gurevich, A. M. Galyavich, A. I. Kaminnyi, V. V. Kashtalap, V. Yu. Mareev, A. V. Susekov, I. I. Shaposhnik |
| |
| 1 - 5 of 5 Items |
|
